Drug pricing body puts cap on trade margin for 42 anti-cancer drugs

Experts say move will not benefit patients as drug prices are already too high and the cap only negligible

Drug pricing policies bent to favour pharma industry, allege health experts

Nearly 83 per cent medicines out of the ambit of price control policy, thus making them out of reach for most patients, say two recent reports